M. Fukuoka

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

N Masuda, M. Fukuoka, Y Kusunoki et al. · Journal of Clinical Oncology · 1992 · 452 citations

Medicine, Oncology, Pharmacology +8

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

S. Negoro, M. Fukuoka, N Masuda et al. · JNCI Journal of the National Cancer Institute · 1991 · 274 citations

Medicine, Oncology, Pharmacology +14

Final results from a phase II trial of ZD1839 ("Iressa") for patients with advanced non-small-cell lung cancer (IDEAL 1)

M. Fukuoka · Medical Entomology and Zoology · 2002 · 171 citations

Pharmacy, Oncology, Pharmacotherapy +8

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.

N Masuda, K Matsui, S Negoro et al. · Journal of Clinical Oncology · 1998 · 101 citations

Medicine, Oncology, Pharmacology +15

294 A randomized phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V), and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): Preliminary analysis

Y Takada, Kiyoyuki Furuse, M. Fukuoka et al. · Lung Cancer · 1997 · 63 citations

Medicine, Oncology, Radiation Oncology +14